Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dialectical Behaviour Therapy (DBT) vs treatment Dissociation/psychoticism ‐ DBT vs. TAUDES7 · patients with borderline personality disorder Psychological therapies for people with borderline personality disorder (2012) · Cochrane | no estimate extracted | 1 study · 20 participants | Low |
Dialectical Behaviour Therapy (DBT) vs general management (GM) according to APA guidelines BPD total severityZAN‐BPD1 total · patients with borderline personality disorder Psychological therapies for people with borderline personality disorder (2012) · Cochrane | no estimate extracted | 1 study · 180 participants | Moderate |
Intervention NR Death · Children with severe malaria Artesunate versus quinine for treating severe malaria (2012) · Cochrane | RR 0.76 [0.65, 0.9] | 4 studies · 5765 participants | High |
Intervention NR Hypoglycaemia episodes · Adults with severe malaria Artesunate versus quinine for treating severe malaria (2012) · Cochrane | RR 0.36 [0.19, 0.68] | 2 studies · 1372 participants | High |
Intervention NR Neurological sequelae at day 28 · Children with severe malaria Artesunate versus quinine for treating severe malaria (2012) · Cochrane | RR 1.23 [0.74, 2.03] | 1 study · 4857 participants | Moderate |
Intervention NR Neurological sequelae at discharge · Children with severe malaria Artesunate versus quinine for treating severe malaria (2012) · Cochrane | RR 1.36 [1.01, 1.83] | 3 studies · 5163 participants | Moderate |
Intervention NR Time to hospital discharge (days) · Children with severe malaria Artesunate versus quinine for treating severe malaria (2012) · Cochrane | no estimate extracted | 3 studies · 113 participants | Moderate |
Intervention NR Hypoglycaemia episodes · Children with severe malaria Artesunate versus quinine for treating severe malaria (2012) · Cochrane | RR 0.62 [0.45, 0.87] | 4 studies · 5765 participants | High |
Intervention NR Death · Adults with severe malaria Artesunate versus quinine for treating severe malaria (2012) · Cochrane | RR 0.61 [0.5, 0.75] | 5 studies · 1664 participants | High |
Intervention NR Neurological sequelae at day 28 · Adults with severe malaria Artesunate versus quinine for treating severe malaria (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Neurological sequelae at discharge · Adults with severe malaria Artesunate versus quinine for treating severe malaria (2012) · Cochrane | RR 2.97 [0.6, 14.64] | 1 study · 1259 participants | Moderate |
Intervention NR Time to hospital discharge (days) · Adults with severe malaria Artesunate versus quinine for treating severe malaria (2012) · Cochrane | no estimate extracted | 2 studies · 113 participants | Moderate |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Arthroplasty instability ‐ inferred from roentgen stereophotogrammetric analysis (Available data analysis) · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | RR 0.47 [0.24, 0.92] | 3 studies · 216 participants | Moderate |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Survival rate of the implant (any change of a component) · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Global Assessment (Patient) · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 1 study · 27 participants | Ungraded |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Functional measures with validated instruments · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 4 studies · 240 participants | Ungraded |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Pain · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Health‐related quality of life measures · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Uncemented fixation with and without hydroxyapatite vs cemented fixation Total adverse event · Patients with osteoarthritis and other non‐traumatic diseases Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other… (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Overall survival (OS) · HER2‐positive early breast cancer patients Trastuzumab containing regimens for early breast cancer (2012) · Cochrane | HR 0.66 [0.57, 0.77] | 8 studies · 9945 participants | High |
Intervention NR Disease free survival (DFS) · HER2‐positive early breast cancer patients Trastuzumab containing regimens for early breast cancer (2012) · Cochrane | HR 0.6 [0.5, 0.71] | 8 studies · 9935 participants | High |
Intervention NR Congestive heart failure (CHF) · HER2‐positive early breast cancer patients Trastuzumab containing regimens for early breast cancer (2012) · Cochrane | RR 5.11 [3, 8.72] | 8 studies · 10281 participants | High |
Intervention NR Left ventricular ejection fraction decline (LVEF) · HER2‐positive early breast cancer patients Trastuzumab containing regimens for early breast cancer (2012) · Cochrane | RR 1.83 [1.36, 2.47] | 7 studies · 7939 participants | Moderate |
Intervention NR Brain metastasis as first site of relapse · HER2‐positive early breast cancer patients Trastuzumab containing regimens for early breast cancer (2012) · Cochrane | RR 1.75 [1.29, 2.38] | 5 studies · 6881 participants | Low |
CBT vs no treatment Outcomes3 · patients with adjustment disorders Interventions to facilitate return to work in adults with adjustment disorders (2012) · Cochrane | no estimate extracted | NR | No studies |
CBT vs no treatment Partial return to work · patients with adjustment disorders Interventions to facilitate return to work in adults with adjustment disorders (2012) · Cochrane | no estimate extracted | 2 studies · 201 participants | Moderate |
CBT vs no treatment Full return to work Scale from: ‐180 to +180 days · patients with adjustment disorders Interventions to facilitate return to work in adults with adjustment disorders (2012) · Cochrane | no estimate extracted | 1 study · 105 participants | Low |
CBT vs no treatment Distress score DASS distress scale from: 0 to 42 points (worse) · patients with adjustment disorders Interventions to facilitate return to work in adults with adjustment disorders (2012) · Cochrane | no estimate extracted | 1 study · 89 participants | Moderate |
BENZODIAZEPINES AS SOLE TREATMENT vs PLACEBO No clinically important response to treatment ‐ short term · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 0.67 [0.44, 1.02] | 6 studies · 382 participants | Very low |
BENZODIAZEPINES vs ANTIPSYCHOTICS Desired sedation ‐ ultra short term ‐ asleep at 12 hours · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 0.75 [0.44, 1.3] | 1 study · 66 participants | Low |
ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS No clinically important response to treatment ‐ ultra short term (at 60 minutes) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 0.07 [0, 1.13] | 1 study · 45 participants | Very low |
ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS No clinically important response to treatment ‐ ultra short term (at 12 hours) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 0.85 [0.51, 1.41] | 1 study · 67 participants | Low |
ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS No clinically important response to treatment ‐ short term (3 weeks or longer) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 0.87 [0.49, 1.54] | 6 studies · 511 participants | Very low |
ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS Leaving the study early due to any reason (overall acceptability of treatment) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 1.36 [0.81, 2.3] | 19 studies · 1185 participants | Very low |
ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS Leaving the study early due to adverse effects (overall tolerability of treatment) ‐ short term · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 3.24 [0.68, 15.45] | 6 studies · 415 participants | Very low |
ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS Desired sedation ‐ ultra short term ‐ tranquillised at 60 minutes · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 1.39 [1.06, 1.83] | 1 study · 45 participants | Low |
ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS Desired sedation ‐ ultra short term ‐ asleep at 12 hours · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 0.85 [0.51, 1.41] | 1 study · 67 participants | Low |
BENZODIAZEPINES AS SOLE TREATMENT vs PLACEBO Leaving the study early due to any reason (overall acceptability of treatment) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 0.89 [0.57, 1.38] | 8 studies · 440 participants | Very low |
BENZODIAZEPINES AS SOLE TREATMENT vs PLACEBO Leaving the study early due to adverse effects (overall tolerability of treatment) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | no estimate extracted | 4 studies · 161 participants | Very low |
BENZODIAZEPINES AS SOLE TREATMENT vs PLACEBO Number of participants tranquillised at endpoint of the study (Desired sedation/tranquillisation) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | no estimate extracted | NR | No studies |
BENZODIAZEPINES vs ANTIPSYCHOTICS No clinically important response to treatment ‐ ultra short term (at 60 minutes) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 0.61 [0.2, 1.86] | 1 study · 44 participants | Very low |
BENZODIAZEPINES vs ANTIPSYCHOTICS No clinically important response to treatment ‐ ultra short term (at 12 hours) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 0.75 [0.44, 1.3] | 1 study · 66 participants | Low |
BENZODIAZEPINES vs ANTIPSYCHOTICS No clinically important response to treatment ‐ short term · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 1.48 [0.64, 3.46] | 2 studies · 112 participants | Very low |
BENZODIAZEPINES vs ANTIPSYCHOTICS Leaving the study early due to any reason (overall acceptability of treatment) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 0.73 [0.45, 1.18] | 13 studies · 738 participants | Very low |
BENZODIAZEPINES vs ANTIPSYCHOTICS Leaving the study early due to adverse effects (overall tolerability of treatment) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | RR 13 [0.78, 216.39] | 5 studies · 444 participants | Very low |
Robotic assistant vs human assistant Conversion to open cholecystectomy · patients undergoing laparoscopic cholecystectomy. Robot assistant versus human or another robot assistant in patients undergoing laparoscopic cholecystectomy (2012) · Cochrane | RR 0.9 [0.25, 3.2] | 2 studies · 133 participants | Very low |
Robotic assistant vs human assistant Operating time · patients undergoing laparoscopic cholecystectomy. Robot assistant versus human or another robot assistant in patients undergoing laparoscopic cholecystectomy (2012) · Cochrane | no estimate extracted | 4 studies · 324 participants | Very low |
Intervention NR Completion of treatment · People with latent tuberculosis Patient education and counselling for promoting adherence to treatment for tuberculosis (2012) · Cochrane | no estimate extracted | 3 studies · 923 participants | Low |
Intervention NR Incidence of active tuberculosis · People with latent tuberculosis Patient education and counselling for promoting adherence to treatment for tuberculosis (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Intervention NR Mortality 30‐day · Adult patients with SIRS or sepsis N‐acetylcysteine for sepsis and systemic inflammatory response in adults (2012) · Cochrane | RR 1.07 [0.8, 1.43] | 11 studies · 930 participants | Moderate |